News Release

WEX appoints Advisory Board

Date: 2000/05/16

International Wex Technologies Inc. (the "company") is pleased to announce that it has selected a renowned group of experts in the fields of Science, Law and Finance as advisors. Each advisor has specialized in depth knowledge that is invaluable to the company as it addresses major issues. These issues include transition from R&D to international conformity with regulatory applications; financial capability during this application process and legal ramifications of the corporate actions while we seek major strategic partners.

The initial Advisory Board members are:

1. Professor Cai, Zhi-Ji, National Institute on Drug Dependence, Beijing Medical University. Internationally recognized as one of the leaders in research on Drug Dependence. Since 1984 a member of WHO Expert Advisory Panel on Drug Dependence and Alcohol problems. He is also on the Executive Board, International Society of Addiction (ISAM).
2. Dr. Anh Ho Ngoc, Montreal, currently, an independent consultant providing pharmaceutical and medical device companies global strategic planning in gaining faster regulatory approval. 1984 - 1999 Dr. Ho was with Rhone Poulenc Rorer Canada Inc., completing the term as Director, Regulatory Affairs. Dr. Ho is Lecturer at the University of Montreal and for the last ten years has taught medicinal stereochemistry.
3. Professor Li, Peizhong, Director of Toxicology Department, Beijing Institute of Pharmacology & Toxicology. President, Toxicology Society of CPS. He holds membership in the GLP Specialist Commission of SDA, State Specialist of SDA for New Drug Assess, Pharmacological Society, Toxicology Society of CNPHARS along with being Editor of the Journal of Chinese Pharmaceutical Sciences and Food and Chemical Toxicology.
4. Dr. Andrew G. Parfitt, Personal Services Contractor, Contract Research with the National Institute of Health, Silver Springs Maryland to develop and exploit new methodology for fluorescence analysis of morphologic dynamics and of synaptic vesicle exo- and endocytosis, using cultures of mouse spinal cord neurons. Dr. Parfitt has over 21 publications to his credit.
5. Professor Zhang, Jun-Tian, Director, Institute of Materia Medica, Chinese Academy of Medical Sciences. Internationally recognized in pharmalogical studies. His memberships include the Chinese Pharmacological Society and more than 200 of his papers have been published in over 10 journals. He is a member of the Scientific Council and Degree Approval Committee of the Chinese Academy of medical Sciences.
6. Professor, Zheng, Jiwang, Director, National Institute on Drug Dependence, Beijing Medical University. Member of the WHO, Commission on Narcotic Drugs.
7. Dr. Franz-Josef Braun, Germany, retired recently to live
   in Canada. During his professional career he was a medical
   internalist. He now enjoys the study and research on medicine.
8. Mr. Pierre A. Lopez, Canadian, 20 years experience in
   the healthcare field primarily in the area of medical devices.
   Director of Burrard Capital Group Inc. and VP/Business Development
   for Destiny Healthcare Inc.
9. Mr. Egon Andre, retired Dutch architect, now a financial
   advisor in Canada & Europe. Former professional soccer player and
   President of the 2nd largest soccer club in Germany (72-84).
10. Mr. A.J. Miller, financial and entrepreneurial businessman
    and executive of The Hamilton Companies LLC. Hamilton Oil was
    among the first major successful North Sea Oil exploration companies.
11. Dr. D.D. Huang, lawyer, China and Canada. Dr. Huang, B.A.,
    LL.B, LL.M., LL.B, LL.D. Associate with Fasken Martineau DuMoulin.
    An adjunct professor at Wuhan University Law School, a Visiting
    professor at Qindao University, and a special Lecturer at Lam Centre
    for International Communication at Simon Fraser University. He is
    expressly authorized by the Canadian Venture Exchange to undertake
    China-related legal work for public companies. He has offices in
    Beijing and Vancouver.
12. Dr. Rolf-Dieter Moenning, lawyer, partner in the leading
    insolvency law firm in Germany. A lecturer of law at the University
    of Bonn and lecture presentations at the University at Cologne. Dr.
    Moenning has offices in the former East Germany and Poland.

Tetrodin(HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin(HT) as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549

Per: Donna Shum, Corporate Secretary